All In Biotech

Drug Trial Radar · NCT00342849

Treatment of Lead-Exposed Children Trial

Treatment of Lead-Exposed Children (TLC) Trial

Last checked: Nov 20, 2026Latest source record: Apr 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 780 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

780

Actual

Start

Jul 15, 1994

Primary completion

Aug 29, 2007

Study completion Jun 10, 2015

Sponsor

Sponsor type
NIH
First posted
Jun 21, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 12 months, up to 33 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Treatment of Lead-Exposed Children (TLC) clinical trial compared the effect of lead chelation with succimer to placebo therapy. TLC was a randomized, double-blind, placebo-controlled clinical trial with sites in Cincinnati and Columbus, Ohio, Philadelphia, Pennsylvania, Baltimore, Maryland and Newark, New Jersey. The study was designed to test outcomes in IQ, neuropsychological function, behavior, physical growth and blood pressure three years after initiation of treatment. Enrollment was conducted between 1994 and 1997, with completion of the initial three-year follow-up in 2000.

Conditions

  • Lead Exposure

Interventions

  • SuccimerDrug

    Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. EfficacyTime frame: Annually

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • University of Medicine and Dentistry of New Jersey

    Newark, New Jersey

  • Childrens Hospital, Columbus

    Columbus, Ohio

  • Childrens Hospital, Philadelphia

    Philadelphia, Pennsylvania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.